MEF2A&MEF2C Recombinant Monoclonal Antibody

MEF2A and MEF2C belong to the myocyte enhancer factor 2 family of transcription factors, playing essential roles in muscle development, neuronal differentiation, and cardiac morphogenesis. These proteins regulate gene expression programs critical for cellular differentiation and have emerged as significant players in understanding developmental biology, neurodegenerative diseases, and cardiac pathologies. Their involvement in diverse signaling pathways makes them valuable targets for researchers investigating tissue-specific gene regulation and disease mechanisms.

This recombinant monoclonal antibody, clone 5C8, offers the consistency and reliability that demanding research applications require. Produced using recombinant technology with a sequence-defined approach, this antibody eliminates the lot-to-lot variability that can compromise experimental reproducibility. The rabbit host-derived IgG format, combined with affinity chromatography purification, ensures high specificity for human MEF2A and MEF2C proteins while minimizing background interference in your assays.

Validation in immunohistochemistry demonstrates robust performance in paraffin-embedded human tissue sections. Testing in human glioma cancer tissue using a Leica Bond system with citrate buffer antigen retrieval at pH 6.0 produced clear, specific staining at 1:100 dilution, with recommended working dilutions ranging from 1:50 to 1:200 depending on your specific tissue and detection system. The antibody is also validated for ELISA applications, providing flexibility across different experimental workflows.

The non-conjugated format allows researchers to select their preferred detection system, while the glycerol-containing buffer formulation supports long-term stability when stored at -20°C or -80°C. This antibody serves as a reliable tool for investigators studying muscle biology, cardiac development, neuronal differentiation, and the transcriptional networks underlying these fundamental biological processes.